Advancing Targeted Genetic Therapies with a Dual-siRNA Approach to Disrupt the Current GLL-1 Monopoly for a More Patient-Focused Treatment Diversity
- Moving beyond appetite suppression by leveraging proprietary dual-siRNA technology to target the root genetic drivers of metabolic dysfunction, promoting the ‘browning’ of white fat and significantly enhancing energy expenditure
- Preserving vital lean muscle mass while achieving selective, transformative fat loss, thereby resolving the critical body composition challenges associated with current therapies and securing healthier, more sustainable long-term metabolic outcomes
- Delivering a disruptive, patient-centric treatment option through a targeted genetic approach that offers the potential for infrequent, twice-yearly dosing, fundamentally changing the treatment paradigm and increasing diversity in the next generation of approved drugs